drugset / Trial / NCT06363370
Human Interferon α1b Inhalation Solution Against Respiratory Syncytial Virus in Children With Lower Respiratory Tract Infections
RandomizedParallel-groupQuadruple-blindTreatment
Summary
To evaluate the efficacy and safety of interferon α1b (GB05) in the treatment of children under 2 years of age with respiratory syncytial virus infection.
Timeline
- Start
- 2024-03-27
- Primary completion
- 2027-06-30
- Completion
- 2027-06-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Human interferon α1b | Unknown | 4 ug/kg | Inhaled |
| Subject | Human interferon α1b | Unknown | 6 ug/kg | Inhaled |